Enhanced antitumor efficacy of telomerase-specific oncolytic adenovirus with valproic acid against human cancer cells

Cancer Gene Therapy

Volumn 19, Issue 11, 2012, Pages 767-772

  Watanabe, Y ^a,b   Hashimoto, Y ^a,b   Kagawa, S ^b   Kawamura, H ^a   Nagai, K ^a   Tanaka, N ^b   Urata, Y ^a   Fujiwara, T ^b  

^a National Institute of Infectious Diseases   (Japan)

^b OKAYAMA UNIVERSITY   (Japan)

Author keywords

oncolytic adenovirus; telomerase; valproic acid

Indexed keywords

COXSACKIE VIRUS AND ADENOVIRUS RECEPTOR; OBP 301; ONCOLYTIC ADENOVIRUS; TELOMELYSIN; TELOMERASE; UNCLASSIFIED DRUG; VALPROIC ACID;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL; CANCER CELL CULTURE; CELL ASSAY; CELL VIABILITY; CONTROLLED STUDY; DRUG EFFICACY; HUMAN; HUMAN CELL; IN VITRO STUDY; LUNG CANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION; RECEPTOR UPREGULATION; VIRUS ATTENUATION; VIRUS RECOMBINANT;

ADENOVIRIDAE; ADENOVIRUS E1A PROTEINS; ADENOVIRUS E1B PROTEINS; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CELL SURVIVAL; COXSACKIE AND ADENOVIRUS RECEPTOR-LIKE MEMBRANE PROTEIN; ENTEROVIRUS; HUMANS; LUNG NEOPLASMS; ONCOLYTIC VIROTHERAPY; ONCOLYTIC VIRUSES; TELOMERASE; VALPROIC ACID; VIRUS REPLICATION;

ADENOVIRIDAE; COXSACKIEVIRUS;

EID: 84867740230     PISSN: 09291903     EISSN: 14765500     Source Type: Journal    
DOI: 10.1038/cgt.2012.57     Document Type: Article

References (28)

1. Hawkins LK, Lemoine NR, Kirn D. Oncolytic biotherapy: a novel therapeutic platform. Lancet Oncol 2002; 3: 17-26.
2. Chiocca EA. Oncolytic viruses. Nat Rev Cancer 2002; 2: 938-950.
3. Parato KA, Senger D, Forsyth PA, Bell JC. Recent progress in the battle between oncolytic viruses and tumours. Nat Rev Cancer 2005; 5: 965-976.
4. Nemunaitis J, Khuri F, Ganly I, Arseneau J, Posner M, Vokes E et al. Phase II trial of intratumoral administration of ONYX-015, a replication-selective adenovirus, in patients with refractory head and neck cancer. J Clin Oncol 2001; 19: 289-298.
5. DeWeese TL, van der PH, Li S, Mikhak B, Drew R, Goemann M et al. A phase I trial of CV706, a replication-competent, PSA selective oncolytic adenovirus, for the treatment of locally recurrent prostate cancer following radiation therapy. Cancer Res 2001; 61: 7464-7472.
6. Reid T, Galanis E, Abbruzzese J, Sze D, Wein LM, Andrews J et al. Hepatic arterial infusion of a replication-selective oncolytic adenovirus (dl1520): phase II viral, immunologic, and clinical endpoints. Cancer Res 2002; 62: 6070-6079.
7. Hamid O, Varterasian ML, Wadler S, Hecht JR, Benson 3rd A, Galanis E et al. Phase II trial of intravenous CI-1042 in patients with metastatic colorectal cancer. J Clin Oncol 2003; 21: 1498-1504.
8. Kawashima T, Kagawa S, Kobayashi N, Shirakiya Y, Umeoka T, Teraishi F et al. Telomerase-specific replication-selective virotherapy for human cancer. Clin Cancer Res 2004; 10(1 Part 1): 285-292.
9. Bergelson JM, Cunningham JA, Droguett G, Kurt-Jones EA, Krithivas A, Hong JS et al. Isolation of a common receptor for Coxsackie B viruses and adenoviruses 2 and 5. Science 1997; 275: 1320-1323.
10. Tomko RP, Xu R, Philipson L. HCAR and MCAR: the human and mouse cellular receptors for subgroup C adenoviruses and group B coxsackieviruses. Proc Natl Acad Sci USA 1997; 94: 3352-3356.
11. Bolden JE, Peart MJ, Johnstone RW. Anticancer activities of histone deacetylase inhibitors. Nat Rev Drug Discov 2006; 5: 769-784.
12. Ma X, Ezzeldin HH, Diasio RB. Histone deacetylase inhibitors: current status and overview of recent clinical trials. Drugs 2009; 69: 1911-1934.
13. Venugopal B, Evans TR. Developing histone deacetylase inhibitors as anti-cancer therapeutics. Curr Med Chem 2011; 18: 1658-1671.
14. Watanabe T, Hioki M, Fujiwara T, Nishizaki M, Kagawa S, Taki M et al. Histone deacetylase inhibitor FR901228 enhances the antitumor effect of telomerase-specific replication-selective adenoviral agent OBP-301 in human lung cancer cells. Exp Cell Res 2006; 312: 256-265.
15. Michaelis M, Doerr HW, Cinatl Jr J. Valproic acid as anti-cancer drug. Curr Pharm Des 2007; 13: 3378-3393.
16. Hrebackova J, Hrabeta J, Eckschlager T. Valproic acid in the complex therapy of malignant tumors. Curr Drug Targets 2010; 11: 361-379.
17. Otsuki A, Patel A, Kasai K, Suzuki M, Kurozumi K, Chiocca EA et al. Histone dea-cetylase inhibitors augment antitumor efficacy of herpes-based oncolytic viruses. Mol Ther 2008; 16: 1546-1555.
18. Kothari V, Joshi G, Nama S, Somasundaram K, Mulherkar R. HDAC inhibitor val-proic acid enhances tumor cell kill in adenovirus-HSVtk mediated suicide gene therapy in HNSCC xenograft mouse model. Int J Cancer 2010; 126: 733-742.
19. Nemunaitis J, Tong AW, Nemunaitis M, Senzer N, Phadke AP, Bedell C et al. A phase I study of telomerase-specific replication competent oncolytic adenovirus (telomelysin) for various solid tumors. Mol Ther 2010; 18: 429-434.
20. Tango Y, Taki M, Shirakiya Y, Ohtani S, Tokunaga N, Tsunemitsu Y et al. Late resistance to adenoviral p53-mediated apoptosis caused by decreased expression of Coxsackie-adenovirus receptors in human lung cancer cells. Cancer Sci 2004; 95: 459-463.
21. Hoti N, Chowdhury W, Hsieh JT, Sachs MD, Lupold SE, Rodriguez R. Valproic acid, a histone deacetylase inhibitor, is an antagonist for oncolytic adenoviral gene therapy. Mol Ther 2006; 14: 768-778.
22. Yamasaki Y, Tazawa H, Hashimoto Y, Kojima T, Kuroda S, Yano S et al. A novel apoptotic mechanism of genetically engineered adenovirus-mediated tumour-specific p53 overexpression through E1A-dependent p21 and MDM2 suppression. Eur J Cancer. e-pub ahead of print 13 Jan 2012, doi:10.1016/j.ejca.2011.12.020.
23. Mora-Garcia Mde L, Duenas-Gonzalez A, Hernandez-Montes J, De la Cruz-Hernandez E, Perez-Cardenas E, Weiss-Steider B et al. Up-regulation of HLA class-I antigen expression and antigen-specific CTL response in cervical cancer cells by the demethylating agent hydralazine and the histone deacetylase inhibitor val-proic acid. J Transl Med 2006; 4: 55.
24. Michaelis M, Michaelis UR, Fleming I, Suhan T, Cinatl J, Blaheta RA et al. Valproic acid inhibits angiogenesis in vitro and in vivo. Mol Pharmacol 2004; 65: 520-527.
25. Endo Y, Sakai R, Ouchi M, Onimatsu H, Hioki M, Kagawa S et al. Virus-mediated oncolysis induces danger signal and stimulates cytotoxic T-lymphocyte activity via proteasome activator upregulation. Oncogene 2008; 27: 2375-2381.
26. Ikeda Y, Kojima T, Kuroda S, Endo Y, Sakai R, Hioki M et al. A novel antiangio-genic effect for telomerase-specific virotherapy through host immune system. J Immunol 2009; 182: 1763-1769.
27. Camphausen K, Cerna D, Scott T, Sproull M, Burgan WE, Cerra MA et al. Enhancement of in vitro and in vivo tumor cell radiosensitivity by valproic acid. Int J Cancer 2005; 114: 380-386.
28. Kuroda S, Fujiwara T, Shirakawa Y, Yamasaki Y, Yano S, Uno F et al. Telomerase-dependent oncolytic adenovirus sensitizes human cancer cells to ionizing radiation via inhibition of DNA repair machinery. Cancer Res 2010; 70: 9339-9348.